49796
document
[ Results of three-year clinical study of prostamol uno efficacy and safety in patients with initial symptoms of prostatic adenoma and risk of its progression ] . Prostamol Uno ( PU ) efficacy and safety were studied in a multicenter , open-population , randomized and comparative trial . PU was given in a single daily dose 320 mg for 36 months to 50 patients with initial symptoms of prostatic adenoma ( PA ) in comparison with 50 matched controls . The trial evaluated PU action on the symptoms progression and quality of life with application of questionnaires IPSS and QoL ( BS ) . It was found that PU treatment relieved PA symptoms by IPSS , while these symptoms progressed in the controls . QoL improved in the study group and deteriorated in the control one . Administration of PU significantly increased urinary flow rate though in the controls urinary flow rate decreased , size of the prostate diminished and increased , respectively . Changes in the PSA were not seen and were insignificant , respectively . The results of the study say that prostamol Uno in a dose 320 mg/day can prevent PA progression without side effects .
49797
Intervention_Pharmacological
prostamol uno
49798
Intervention_Pharmacological
Prostamol Uno ( PU )
49799
Intervention_Pharmacological
PU
49800
Intervention_Pharmacological
PU
49801
Outcome_Other
efficacy
49802
Outcome_Other
safety
49803
Outcome_Other
efficacy
49804
Outcome_Other
safety
49805
Outcome_Physical
symptoms progression
49806
Outcome_Other
quality of life
49807
Outcome_Physical
questionnaires IPSS and
49808
Outcome_Other
QoL ( BS )
49809
Outcome_Physical
QoL
49810
Outcome_Physical
urinary flow rate
49811
Outcome_Physical
urinary flow rate
49812
Outcome_Physical
size of the prostate
49813
Outcome_Physical
PSA
49814
Outcome_Adverse-effects
side effects
49815
Participant_Sample-size
50 patients
49816
Participant_Condition
prostatic adenoma ( PA )
49817
Participant_Sample-size
50 matched controls